0.0222
price up icon2.14%   0.000464
after-market Handel nachbörslich: .02 -0.00216 -9.76%
loading
Schlusskurs vom Vortag:
$0.0217
Offen:
$0.022
24-Stunden-Volumen:
3,669
Relative Volume:
0.22
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-32.63%
1M Leistung:
-61.65%
6M Leistung:
-78.27%
1J Leistung:
-35.76%
1-Tages-Spanne:
Value
$0.022
$0.0251
1-Wochen-Bereich:
Value
$0.0217
$0.0354
52-Wochen-Spanne:
Value
$0.0217
$34.93

Geovax Labs Inc Stock (GOVXW) Company Profile

Name
Firmenname
Geovax Labs Inc
Name
Telefon
678 384 7220
Name
Adresse
1900 Lake Park Drive, Suite 380, Smyrna
Name
Mitarbeiter
14
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
GOVXW's Discussions on Twitter

Vergleichen Sie GOVXW mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GOVXW
Geovax Labs Inc
0.0222 0 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.19 127.64B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
603.58 65.95B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
656.65 37.92B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
273.55 32.98B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
254.16 26.92B 3.81B -644.79M -669.77M -6.24

Geovax Labs Inc Aktie (GOVXW) Neueste Nachrichten

pulisher
03:06 AM

D. Boral Capital Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $9.00 - Defense World

03:06 AM
pulisher
02:26 AM

GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Analysts - Defense World

02:26 AM
pulisher
May 04, 2025

Geode Capital Management LLC Has $223,000 Holdings in GeoVax Labs, Inc. (NASDAQ:GOVX) - Defense World

May 04, 2025
pulisher
May 03, 2025

Geovax highlights progress on mpox vaccine and COVID-19 trial advancements - MSN

May 03, 2025
pulisher
May 02, 2025

GeoVax Labs Earnings Call: Mixed Sentiment and Future Prospects - TipRanks

May 02, 2025
pulisher
May 02, 2025

Geovax Labs (GOVX) Faces Price Target Reduction by Analyst | GOV - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga

May 02, 2025
pulisher
May 02, 2025

GeoVax Labs Reports Q1 2025 Progress Amid Challenges - TipRanks

May 02, 2025
pulisher
May 01, 2025

Earnings call transcript: GeoVax Q1 2025 reveals revenue from BARDA contract - Investing.com

May 01, 2025
pulisher
May 01, 2025

GeoVax Labs Q1 2025 Earnings Call Transcript - MarketBeat

May 01, 2025
pulisher
Apr 28, 2025

Geovax Labs is a buy, Roth says - Cantech Letter

Apr 28, 2025
pulisher
Apr 27, 2025

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - ADVFN

Apr 27, 2025
pulisher
Apr 25, 2025

GOVX’s 2023 Market Dance: Down -59.51% – Time to Invest? - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

Geovax Labs Inc (GOVX) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com

Apr 25, 2025
pulisher
Apr 24, 2025

GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress - Yahoo Finance

Apr 24, 2025
pulisher
Apr 23, 2025

GeoVax to Host Q1 2025 Financial Results Conference Call, Spotlight COVID-19 Vaccine and Cancer Therapy Progress - citybuzz -

Apr 23, 2025
pulisher
Apr 23, 2025

GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025 - The Globe and Mail

Apr 23, 2025
pulisher
Apr 22, 2025

GeoVax Bolsters Technical Development with Seasoned Biologics Executive - citybuzz -

Apr 22, 2025
pulisher
Apr 22, 2025

GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations - The Globe and Mail

Apr 22, 2025
pulisher
Apr 20, 2025

Analysts Issue Forecasts for GeoVax Labs FY2029 Earnings - Defense World

Apr 20, 2025
pulisher
Apr 19, 2025

HC Wainwright Estimates GeoVax Labs FY2025 Earnings - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

Alliance Global Partners Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $8.50 - Defense World

Apr 18, 2025
pulisher
Apr 18, 2025

HC Wainwright Reiterates Buy Rating for GeoVax Labs (NASDAQ:GOVX) - Defense World

Apr 18, 2025
pulisher
Apr 18, 2025

Q2 EPS Estimates for GeoVax Labs Lowered by Noble Financial - Defense World

Apr 18, 2025
pulisher
Apr 16, 2025

GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates - Yahoo Finance

Apr 16, 2025
pulisher
Apr 16, 2025

GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital - Yahoo Finance

Apr 16, 2025
pulisher
Apr 16, 2025

GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum - Yahoo Finance

Apr 16, 2025
pulisher
Apr 15, 2025

Geovax Labs stock hits 52-week low at $0.78 amid market challenges By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Top Midday Decliners - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

These Numbers Reveal How Powerful Geovax Labs Inc (NASDAQ: GOVX) Stock Is - stocksregister.com

Apr 15, 2025
pulisher
Apr 15, 2025

GeoVax Labs (GOVX) Faces Setback with Price Target Reduced by Ro - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

GeoVax Labs (GOVX) Faces Setback with Price Target Reduced by Roth Capital | GOVX Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

GeoVax to Present at the Emerging Growth Conference on April 16, 2025 - Yahoo Finance

Apr 15, 2025
pulisher
Apr 15, 2025

GeoVax (GOVX) Faces Setback with Termination of COVID-19 Vaccine Project | GOVX Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

GeoVax's COVID-19 Vaccine Study Ended by Funding Agency; Shares Fall - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

GeoVax Labs (GOVX) Faces Setback as BARDA-Funded Trial Ends | GO - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Geovax Labs stock hits 52-week low at $0.78 amid market challenges - Investing.com Canada

Apr 15, 2025
pulisher
Apr 15, 2025

GeoVax to Present Clinical Data at Upcoming April Industry Events - Yahoo Finance

Apr 15, 2025
pulisher
Apr 15, 2025

GeoVax Labs (GOVX): Price Target Lowered Amid BARDA Project Pause | GOVX Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

GeoVax Labs contract with BARDA terminated By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

GeoVax Labs Got Written Notification From Advanced Technology International - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

GeoVax tumbles as HHS ends mid-stage COVID vaccine trial - TradingView

Apr 14, 2025
pulisher
Apr 14, 2025

GeoVax Labs contract with BARDA terminated - Investing.com

Apr 14, 2025
pulisher
Apr 12, 2025

Geovax labs director John Spencer buys $9,800 in stock - Investing.com Australia

Apr 12, 2025
pulisher
Apr 12, 2025

GeoVax Labs (NASDAQ:GOVX) Earns “Buy” Rating from D. Boral Capital - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Geovax labs director John Spencer buys $9,800 in stock By Investing.com - Investing.com Canada

Apr 11, 2025
pulisher
Apr 10, 2025

Geovax labs VP John Sharkey acquires $5,940 in common stock By Investing.com - Investing.com Canada

Apr 10, 2025
pulisher
Apr 10, 2025

GeoVax Labs (GOVX) Gains Favor with BARDA Contract Amid FDA Vacc - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Geovax labs VP John Sharkey acquires $5,940 in common stock - Investing.com Australia

Apr 10, 2025
pulisher
Apr 10, 2025

GeoVax Labs, Inc. (NASDAQ:GOVX) Given Average Recommendation of “Buy” by Analysts - Defense World

Apr 10, 2025

Finanzdaten der Geovax Labs Inc-Aktie (GOVXW)

Es liegen keine Finanzdaten für Geovax Labs Inc (GOVXW) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$72.58
price up icon 0.39%
$21.55
price up icon 0.33%
$33.00
price up icon 0.33%
$28.02
price up icon 0.43%
$101.10
price down icon 3.66%
biotechnology ONC
$254.16
price down icon 0.63%
Kapitalisierung:     |  Volumen (24h):